NRG1 variant effects in patients with Hirschsprung disease

Gunadi
Nova Yuli Prasetyo Budi
Raman Sethi
Aditya R. Fauzi
Alvin S. Kalim

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/publichealthsciences_articles

Recommended Citation
Gunadi, Budi NYP, Sethi R, Fauzi AR, Kalim AS, Indrawan T, Iskandar K, Makhmudi A, Adrianto I, and San LP. NRG1 variant effects in patients with Hirschsprung disease. BMC Pediatr 2018; 18(1):292.
Authors
Gunadi, Nova Yuli Prasetyo Budi, Raman Sethi, Aditya R. Fauzi, Alvin S. Kalim, Taufik Indrawan, Kristy Iskandar, Akhmad Makhmudi, Indra Adrianto, and Lai P. San

This article is available at Henry Ford Health System Scholarly Commons: https://scholarlycommons.henryford.com/publichealthsciences_articles/165
NRG1 variant effects in patients with Hirschsprung disease

Gunadi1*, Nova Yuli Prasetyo Budi1, Raman Sethi2,3, Aditya Rifqi Fauzi1, Alvin Santoso Kalim1, Taufik Indrawan1, Kristy Iskandar4, Akhmad Makhmudi1, Indra Adrianto5 and Lai Poh San2,3

Abstract

Background: Hirschsprung disease (HSCR) is a heterogeneous genetic disorder characterized by absence of ganglion cells along the intestines resulting in functional bowel obstruction. Mutations in neuregulin 1 (NRG1) gene have been implicated in some cases of intestinal aganglionosis. This study aims to investigate the contribution of the NRG1 gene to HSCR development in an Indonesian population.

Methods: We analyzed the entire coding region of the NRG1 gene in 54 histopathologically diagnosed HSCR patients.

Results: All patients were sporadic non-syndromic HSCR with 53/54 (98%) short-segment and 1/54 (2%) long-segment patients. NRG1 gene analysis identified one rare variant, c.397G > C (p.V133 L), and three common variants, rs7834206, rs3735774, and rs75155858. The p.V133 L variant was predicted to reside within a region of high mammalian conservation, overlapping with the promoter and enhancer histone marks of relevant tissues such as digestive and smooth muscle tissues and potentially altering the AP-4_2, BDP1_disc3, Egr-1_known1, Egr-1_known4, HEN1_2 transcription factor binding motifs. This p.V133 L variant was absent in 92 non-HSCR controls. Furthermore, the rs7834206 polymorphism was associated with HSCR by case–control analysis (p = 0.037).

Conclusions: This study is the first report of a NRG1 rare variant associated with HSCR patients of South-East Asian ancestry and provides further insights into the contribution of NRG1 in the molecular genetic pathogenesis of HSCR.

Keywords: Hirschsprung disease, Indonesia, NRG1 variant, Transcription factor binding motif

Background

Hirschsprung disease (HSCR), a heterogeneous genetic disorder, is characterized by the lack of ganglion cells along varying lengths of the intestines resulting in functional obstruction among children [1]. According to the length of aganglionosis, HSCR is categorized into three major types: short-segment (aganglionosis up to the upper sigmoid colon), long-segment (aganglionosis up to the splenic flexure and beyond) and total colonic aganglionosis (TCA) [1, 2].

The incidence of HSCR varies among populations with 15, 21 and 28 cases per 100,000 live births in Caucasians, Africans and Asians, respectively [1, 2]. These differences might be influenced by susceptibility factors such as the REarranged during Transfection (RET) rs2435357 risk allele frequency [3]. Our recent studies clearly demonstrated the presence of a higher frequency of RET rs2435357 susceptibility allele in Indonesian ancestry (50%) [4, 5]. Nevertheless, we observed that semaphorin 3 common variant had different effects on HSCR depending on the ethnic background [6].

HSCR is a complex genetic disorder and at least 15 genes have been implicated in the development of HSCR, with the gene encoding the receptor tyrosine kinase RET accounting for up to 21% of sporadic cases [7]. These genes encode proteins that are important for the enteric ganglia development and are classified into three groups: 1) those that are associated with RET pathways (RET, GFRα1, GDNF, NTN, PSPN); 2) those implicated in endothelin type B receptor/EDNRB (EDNRB, EDN3, ECE-1) pathways; and 3) transcription factors that influence both RET and/or EDNRB pathways (SOX10, ZFXH1B, PHOX2B) [7, 8].

Neuregulin 1 (NRG1) has been implicated as a disease susceptibility gene in Chinese [9, 10]. Both common (single
nucleotide polymorphisms, SNPs) and rare variants of this gene are reported to confer disease risk with over-representation in patient cohorts. However, in the first study on Caucasian, Luzón-Toro et al. [11] did not find any significant association of NRG1 SNPs in Spanish HSCR suggesting that the association of such common polymorphisms to the disease may be restricted to specific populations. Furthermore, they found three novel NRG1 rare variants that were hypothesized to have functional consequences during embryonic development of HSCR which could lead to HSCR in their patients. It is believed that NRG1 plays an essential role in the signaling pathway of the enteric nervous system (ENS) [9–12]. In addition, the development of ENS requires a balance of neurogenesis and gliogenesis by RET/GDNF and ERBB2/NRG1 pathways, respectively. Nrg1 suppresses Gdnf-induced neuronal differentiation and Gdnf negatively controls Nrg1-signaling by reducing the expression of its receptor, ErbB2 [13].

Recently, we studied two previously reported NRG1 SNPs and demonstrated that that only one common variant rs7835688 as a genetic risk factor for Indonesian HSCR patients. It is suggested that the association of such common polymorphisms to the disease may be restricted to specific populations. The in silico tools used to predict coding variant effects on protein function were SIFT (http://sift.jcvi.org/), PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), LRT (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910100/), Mutation Taster (http://www.mutationtaster.org), Mutation Assessor (http://mutationassessor.org) and DANN (https://cbcl.ics.uci.edu/public_data/DANN/) (Additional file 1).

To identify mutations, all 16 exons of the NRG1 that had been PCR amplified in 20 fragments were sequenced using Sanger sequencing analysis with a BigDye Terminator V3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA). The products were separated and analyzed on a 3730xl Genetic Analyzer (Applied Biosystems, Foster City, CA) using DNA Sequencing Analysis Software (Applied Biosystems, Foster City, CA) [17, 18].

Bioinformatics analyses

Data from the 1000 Genomes Project (http://www.internationalgenome.org) and ExAC (http://exac.broadinstitute.org) ancestry controls were utilized for comparison of variant frequencies among population. The in silico tools used to predict coding variant effects on protein function were SIFT (http://sift.jcvi.org/), PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), LRT (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910100/), Mutation Taster (http://www.mutationtaster.org), Mutation Assessor (http://mutationassessor.org) and DANN (https://cbcl.ics.uci.edu/public_data/DANN/) (Additional file 1).

SIFT predicts whether a change of amino acid change in a protein will have an impact on phenotype. This calculation is based on the premise that protein evolution is correlated with protein function, the more important positions of amino acids will correspondingly be more conserved in an alignment of the protein family. A SIFT score ranges from 0 to 1 and is classified as two groups: 1) predicted damaging if score ≤ 0.05; and 2) tolerated if score > 0.05 (http://sift.jcvi.org/). PolyPhen-2 score calculates the possible effect of a change of amino acid on the human protein structure and function. Its score ranges from 0 to 1 and consists of three interpretations: 1) benign (≤ 0.452 in PolyPhen2 HDiv and ≤ 0.446 in PolyPhen2 HVar); 2) probably damaging (0.453 to 0.956 in PolyPhen2 HDiv and 0.447 to 0.909 in PolyPhen2 HVar); and 3) probably damaging (≥ 0.957 in PolyPhen2 HDiv and ≥ 0.909 in PolyPhen2 HVar) (http://genetics.bwh.harvard.edu/pph2/). Mutation Taster determines the disease potential of an alteration of amino acid using the Bayes classifier, with four possible analysis: 1) disease causing (i.e. probably deleterious); 2) disease causing automatic (i.e. known to be deleterious); 3) polymorphism (i.e. probably harmless); and 4) polymorphism automatic (i.e. known to be harmless) (http://www.mutationtaster.org). DANN uses deep neural network (DNN) algorithm to predict pathogenicity of variants and scores from 0.98 to 1 are considered to be protein disrupting (Additional file 1). All these tools predict whether a mutation leads to damaging function that may be potentially disease causing but it is well acknowledged that such in silico
tools are only used as predictive guides and may not necessarily agree with each other as they can yield conflicting results [19–21].

The predicted conservation scores of variants were determined using GERP (http://mendel.stanford.edu/SidowLab/downloads/gerp/index.html), PhyloP (http://ccg.vital-it.ch/mga/hg19/phylop/phylop.html), and SiPhy (http://portals.broadinstitute.org/genome_bio/siphy/index.html) tests. The clinical significance of variants was analyzed using ClinVar tool (https://www.ncbi.nlm.nih.gov/clinvar/). The HaploReg database (https://pubs.broadinstitute.org/mammals/haploreg haploreg.php) was utilized to evaluate the impact of the variant by annotation of epigenomic, conservation and regulatory motif information (Additional file 1).

**Statistical genetic analysis**
Chi-square test was used to establish p-values for the case–control association analysis for NRG1 variants (rs7834206, rs3735774, and rs75155858). A p-value less than 0.05 was considered significant.

**Results**
All fifty-four patients (n = 54) were sporadic non-syndromic HSCR. Neither familial nor syndromic HSCR were included in this study. According to the degree of aganglionosis, the distribution of the cases was 53/54 (98%) short-segment, 1/54 (2%) long-segment and none were TCA. The mean age at diagnosis and age at definitive operation was 34.6 ± 44.5 months (range, 1–174 months) and 38.7 ± 43.9 months (range, 1–175 months), respectively (Table 1).

**DNA analysis covering coding regions of all 16 exons of NRG1 gene in our cohort of 54 Indonesian HSCR**
patients demonstrated the presence of four variants. These variants were: one rare missense variant, c.397G > C, in exon 7, which led to a substitution of valine with leucine (p.V133 L) in one HSCR patient (Fig. 1), and three common variants, rs7834206, rs3735774, and rs75155858 (Table 2).

We compared the observed NRG1 rare variant allele frequency in Indonesian HSCR patients with those reported for the 1000 Genomes Project and ExAC ancestry controls. The frequency of c.397G > C (p.V133 L) rare variant in our HSCR patients (0.9%) was higher than those reported for the 1000 Genomes and ExAC

Table 2 NRG1 variants found in Indonesian HSCR patients

| Nucleotide | Amino Acid | Reference | Frequency | Odds ratio (95% CI) | p-value |
|------------|------------|-----------|-----------|---------------------|---------|
| c.-97C > A | 5'-UTR     | rs7834206 | Genotype | 1.79 (1.03–3.11) | 0.037*  |
|            |            |           | CC: 26   |         |        |
|            |            |           | CA: 24   |         |        |
|            |            |           | AA: 4    |         |        |
|            |            |           | C: 76    |         |        |
|            |            |           | A: 32    |         |        |
| c.136G > A | p.G46R     | rs3735774 | Genotype | 0.79 (0.33–1.89) | 0.59    |
|            |            |           | GG: 47   |         |        |
|            |            |           | GA: 6    |         |        |
|            |            |           | AA: 1    |         |        |
|            |            |           | G: 100   |         |        |
|            |            |           | A: 8     |         |        |
| c.2298G > T | p.G613 V  | rs75155858| Genotype | 1.02 (0.62–1.67) | 0.94    |
|            |            |           | GG: 26   |         |        |
|            |            |           | GT: 18   |         |        |
|            |            |           | TT: 10   |         |        |
|            |            |           | G: 70    |         |        |
|            |            |           | T: 38    |         |        |
| c.397G > C | p.V133 L   | rs35641374| Genotype |         |         |
|            |            |           | GG: 53   |         |        |
|            |            |           | GC: 1    |         |        |
|            |            |           | CC: 0    |         |        |
|            |            |           | G: 107   |         |        |
|            |            |           | C: 1     |         |        |

* a p-value of < 0.05 was considered significant; **, NP_039253; ***, NP_039251

Table 3 NRG1 variants frequency in Indonesian HSCR and population databases

| Variant | HSCR patients | Indonesian control | 1000 Genomes* | ExAC** | p-value vs. 1000 Genomes | p-value vs. ExAC |
|---------|---------------|--------------------|---------------|--------|--------------------------|------------------|
| c.397G > C (p.V133 L) | 0.009 | 0 | 0 | 0.0007 | < 0.0001 | < 0.0001 |
| rs7834206 | 0.30 | 0.19 | 0.18 | N/A | < 0.0001 | N/A |
| rs3735774 | 0.07 | 0.09 | 0.09 | 0.07 | 1 | 1 |
| rs75155858 | 0.35 | 0.35 | 0.35 | 0.35 | 1 | 1 |

*, a p-value of < 0.05 was considered significant; **, East Asian ancestries; HSCR, Hirschsprung disease; N/A, not available
Table 4 Prediction of NRG1 variants effects on protein function

| Variant          | SIFT     | Polyphen2 – HDIV | Polyphen2 – HVAR | LRT      | Mutation Taster        | Mutation Assessor | FATHMM    | CADD      | DANN                  |
|------------------|----------|------------------|------------------|----------|------------------------|-------------------|-----------|-----------|-----------------------|
| c.397G > C       | 0.22 (tolerated) | 0.029 (benign)   | 0.02 (benign)    | 0 (neutral) | Disease causing         | 0.805 (low)       | 12.29 (benign) | 0.6874 (non-protein disrupting) |
| (p.V133 L)       | rs7834206| 0                | 0                | 0         | 0                      | 0 (tolerated)     | 0         | 0         | 0.6874 (non-protein disrupting) |
| rs3735774        | 0.36 (tolerated) | 0.003 (benign)   | 0.004 (benign)   | 0         | Polymorphism            | 0.345 (neutral)   | 8.83 (benign) | 0.9957 (protein disrupting) |
| rs75155858       | 0        | 0.962 (probably damaging) | 0.784 (possibly damaging) | 0.004 (neutral) | Polymorphism automatic | 0.895 (low)       | 0.4 (tolerated) | 14.6 (benign) | 0.9934 (protein disrupting) |

Prediction scores interpretation:

- **Method**
  - **SIFT**: Deleterious cut-off
    - $< 0.05$
  - **Polyphen2 HDIV**: $> 0.453$
  - **Polyphen2 HVAR**: $> 0.447$
  - **LRT**: $> 0.999$
  - **Mutation Taster**: D (disease causing) or P (polymorphism)
  - **Mutation Assessor**: $> 0.65$
  - **FATHMM**: $< -1.5$
  - **CADD**: $> 15$
  - **DANN**: $> 0.98$ (protein disrupting)
  - $0.93 - 0.98$ (splice site/promoter region)
  - $< 0.93$ (non-protein disrupting)
ancestry controls (0 and 0.07%, respectively, \( p < 0.0001 \)) (Table 3).

Next, we analyzed the potential damaging effect of the rare variant (p.V133 L) using the following function prediction algorithms: SIFT, PolyPhen-2 (HDiv and HVar), LRT, Mutation Taster, Mutation Assessor, FATHMM, CADD and DANN (Table 4). Although SIFT and PolyPhen-2 analysis of p.V133 L showed the variant as being tolerated (0.22) and benign (0.029 in PolyPhen2 HDiv and 0.02 in PolyPhen2 HVar), respectively, p.V133 L was predicted to be disease causing by Mutation Taster and DANN. According to the conservation scores prediction using GERP and PhyloP vertebrate, the p.V133 L variant reached a deleterious threshold with a score of 4.26 and 1.799, respectively (Table 5) [26, 23]. However, ClinVar reported the clinical significance of the p.V133 L variant as likely benign (Table 6).

We then used the HaploReg database to assess the regulatory potential of this variant. This variant was predicted to reside within a region of high mammalian conservation, overlapping with the promoter and enhancer histone marks of relevant tissues such as digestive and smooth muscle tissues and altering AP-4_2, BDP1_disc3, Egr-1_known1, Egr-1_known4, HEN1_2 transcription factor binding motifs (Table 7). When 92 Indonesian control subjects were screened, none carried this variant, suggesting that it is not likely to be a common variant in our population.

Next, we compared the risk allele frequencies of the three NRG1 common variants in 54 Indonesian HSCR cases and 92 Indonesian controls (Table 2). For rs7834206, the risk allele (A) has a frequency of 29.6% (32/108) in cases as compared to 19% (35/184) in controls, and the frequency in patients is 1.79-fold higher and significantly so (\( p = 0.037 \)). The risk allele frequencies of rs3735774 (allele A) and rs75155858 (allele T) are similar in cases and controls [allele frequency in cases: 7.4% (8/108) and 35.2% (38/108); in controls: 3.7% (7/184) and 34.8% (64/184), respectively, (with \( p = 0.59 \) and 0.94), respectively] (Table 2). The genotypes of NRG1 rs7834206, rs3735774, and rs75155858 were in Hardy–Weinberg equilibrium with the \( p \)-values of 0.37, 0.59, and 0.94, respectively.

Furthermore, we checked the rare and common variants from previous studies [10, 11] in Indonesian HSCR patients. We could not detect any rare variant found in previous studies [10, 11] in our cohort of HSCR patients, and the following rare variants [10] have been now considered as common variants: p.H347Y (rs758262997), p.P356L (rs776232660), p.A511T (rs76858256), and p.P608A (rs201432506) (http://www.internationalgenome.org).

Discussion

In this study, we have conducted a mutational screening of the NRG1 gene in an Indonesian cohort of HSCR patients. We found three non-synonymous variants and one nucleotide substitution variant in the 5’ untranslated region of the NRG1 gene. Among them, p.V133 L located in the EGF-like domain within the NRG1 protein, was considered a rare variant in our population since it was absent in 92 non-HSCR controls. There was conflicting results from computational prediction programs with regards to the pathogenicity of p.V133 L and it has been classified as benign in ClinVar. However, the location of this variant in a well conserved and important histone and motif binding region suggests that it may have a regulatory function on gene expression.

The EGF domain where p.V133 L resides has been shown to be necessary for the activation of ErbB receptors [24]. The variant might also affect the SOX10-mediated maintenance of ENS progenitors since the receptors for Nrg1 and ErbB3 are regulated by Sox10 [25, 26]. Moreover, the ENS development involves a balance of neurogenesis and gliogenesis by RET/GDNF and ERBB2/NRG1 pathways, respectively [13]. Therefore, we might suggest that p.V133 L will have an effect in intestinal aganglionosis in our HSCR patient by two mechanisms: 1) affecting the SOX10-mediated maintenance of ENS progenitors, and 2)
altering the balance of neurogenesis and gliogenesis during ENS development. The p.V133 L variant was absent in 92 non-HSCR population. Thus, we considered the variant as rare in our population. The presence of this variant was also higher in our patients than those reported in the 1000 Genomes and ExAC ancestry controls (0.9% vs. 0 vs. 0.07%). Previous studies reported NRG1 rare variants to be implicated in the development of ENS and HSCR [10, 11]. Interestingly, the frequency of this NRG1 rare variant found in Indonesian [1/54 (1.8%) patients] was similar to those of Caucasian and Chinese probands [3/207 (1.4%) and 13/358 (3.6%) patients, respectively; with \( p = 0.45 \) [10, 11]. Furthermore, the NRG1 rs7835688 common variant was originally associated with HSCR in Chinese patients [9] and has been similarly observed in other Asian ancestry cases [4, 27], but these associations were not replicated in any Caucasian population [11, 28].

We were able to find evidence of the genetic effect of NRG1 rs7834206 in Indonesian HSCR cases. Our study shows that NRG1 rs7834206 is a genetic risk factor for HSCR with a background allele frequency of ~19% in Indonesian populations (Table 3). The risk allele at rs7834206 (0.19 vs. 0.18) in Indonesian controls has a similar frequency to subjects of Asian ancestry in the 1000 Genomes dataset (\( p = 0.80 \)). Furthermore, a recent meta-analysis study showed that NRG1 polymorphisms are risk factors for HSCR in Asians but not in Caucasians [29]. Therefore, our findings strengthen the notion of the potential damaging role of NRG1 common variants in HSCR patients of Asian ancestries. It should be noted that the small sample size in this study poses a potential limitation and a significantly larger number of patients are needed to validate these observations. Future investigations on larger cohorts will clarify the exact role of the two variants, rs7834206 and p.V133 L in HSCR in Indonesian population. Moreover, moving beyond the prediction effect of mutations, further in vitro or in vivo functional studies are required to shed light on the actual effect of any variant.

Although there have been previous studies correlating NRG1 SNPs with disease association in HSCR, these have only been reported in three populations, namely Chinese, Caucasian, and Thais [10, 11, 27, 28]. Indeed, contrary to the findings in Chinese, Luzón-Toro et al. [11] failed to find association of NRG1 variants with HSCR phenotype in Spanish patients and suggested that this could be due to population differences. In the Thai patients, only four NRG1 SNPs were selected for association studies and disease correlation was found in Thai-Chinese but not Thai-Muslim patients suggesting ethnicity differences [27]. Our present study is unique in this being a comprehensive screen of NRG1 gene in Indonesian HSCR patients. As indicated in all the above studies, it is important to verify the role of NRG1 variants in different population groups due to ethnicity differences. Furthermore, the SNPs in this study, namely the three common variants (rs7834206, rs3735774, and rs75155858) have not been previously investigated in all the other reported studies [10–12]. Since the allele frequencies of some common variants have been known to vary among different ethnic groups within Asian population, it is thus important to clarify the relationship of NRG1 SNPs in Indonesian patients [30].

In view of recent interest in the role of NRG1 in HSCR, it is not surprising that there is increasing evidence showing the contributions of both common and rare variants of this gene to disease risk. Our study reinforces this growing body of information showing the presence of NRG1 risk variants that may interact with other alleles such as RET, GDNF, ErbB or SOX10 as well as other susceptibility factors in leading to HSCR risk, and demonstrating that there are population differences in the contributions of the different risk alleles.

### Conclusion

This study is the first report of a NRG1 rare variant associated with HSCR patients in South-East Asian ancestry and adds insights into the role of NRG1 in the molecular pathogenesis of HSCR.

---

**Table 6** Clinical significance of NRG1 variants

| Variant              | Clinical Significance | ClinVar ID |
|----------------------|-----------------------|------------|
| c.397G > C (p.V133 L) | Likely benign         | RCV000202884:1 |
| rs7834206            | 0                     | 0          |
| rs3735774            | 0                     | 0          |
| rs75155858           | 0                     | 0          |

**Table 7** HaploReg v4.1 bioinformatics database search of NRG1 p.V133 L

| Variant              | Histone H3K4me1 (Enhancer) | Histone H3K4me3 (Promoter) | Histone H3K9ac (Promoter) | Motifs Change                  |
|----------------------|----------------------------|----------------------------|---------------------------|--------------------------------|
| c.397G > C (p.V133 L)| Gastric                    | Duodenum Smooth Muscle, Colon Smooth Muscle, Stomach Smooth Muscle, Fetal Stomach, Fetal Intestine Small, Fetal Intestine Large | Stomach Mucosa | AP-4_2, BDP1_disc3, Egr-1_known1, Egr-1_known4, HEN1_2 |
Additional file

Additional file 1: Supplementary material URLs. (DOC 22 kb)

Abbreviations
ENS: Enteric nervous system; HSCR: Hirschsprung disease; NRG1: Neuregulin 1; PCR: Polymerase chain reaction; RET: Rearranged during Transfection; SNPs: Single nucleotide polymorphisms; TCA: Total colonic aganglionosis

Acknowledgements
The abstract has been presented at the 12th Asia-Pacific Conference on Human Genetics in Bangkok, Thailand at November 8-10, 2017. We would like to thank the patients and their families who have contributed to these studies. We also thank Prof. Paul KH Tam (The University of Hong Kong) for critically reading the manuscript and his suggestions. We are also thankful to Yuenleni, Faial Farhan Akmal, Fiko Riantono, Hamzah Muhammad Hafiq, and Rabikah Yahya (Faculty of Medicine, UGM) for technical assistances and Harini Natalia (Institutional Review Board, Faculty of Medicine, UGM/Dr. Sardjito Hospital) for ethical clearance management, and all those who provided excellent technical support and assistance during the study.

Funding
The studies were supported by the grant from the Director General for the Strengthening of Research and Development, Indonesian Ministry of Research, Technology and Higher Education (“1700/UN1/DITLIT/DIT-LIT/LT/2018” to G).

Availability of data and materials
All data generated or analyzed during this study are included in the submission. The raw data are available from the corresponding author on reasonable request.

Authors’ contribution
Author contributions: G, KI, and AM conceived the study. G and IA drafted the manuscript; KI, AM, RS, and LPS critically analyzed the data and reviewed the manuscript; NYPB, ARF, TI, and ASK performed the experimental PCR-based work for Sanger sequencing. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The Ethical Committee of Faculty of Medicine, Universitas Gadjah Mada/Dr. Sardjito Hospital gave approval for this study (KE/FK/787/EC/2015). Written informed consent was obtained from all parents of the subjects for this study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Pediatric Surgery Division, Department of Surgery, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta 55281, Indonesia. 2Department of Pediatrics, Yoo Loo Lin School of Medicine, National University of Singapore, Singapore 117549, Singapore. 3The Kho Teck Puat-National University Children’s Medical Institute, National University Hospital, Singapore 119228, Singapore. 4Department of Child Health, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/UGM Academic Hospital, Yogyakarta 55291, Indonesia. 5Department of Public Health Sciences, Henry Ford Health System, Detroit, MI 48202, USA.
26. Paratore C, Eichenberger C, Suter U, et al. Sox10 haploinsufficiency affects maintenance of progenitor cells in a mouse model of Hirschsprung disease. Hum Mol Genet. 2002;11:3075–85.

27. Phusantisampan T, Sangkhathat S, Phongdara A, et al. Association of genetic polymorphisms in the RET-protooncogene and NRG1 with Hirschsprung disease in Thai patients. J Hum Genet. 2012;57:286–93.

28. Kapoor A, Jiang Q, Chatterjee S, et al. Population variation in total genetic risk of Hirschsprung disease from common RET, SEMA3 and NRG1 susceptibility polymorphisms. Hum Mol Genet. 2015;24:2997–3003.

29. Jiang M, Li C, Cao G, et al. Effects of NRG1 polymorphisms on Hirschsprung's disease susceptibility: a meta-analysis. Sci Rep. 2017;7:9913.

30. Tajima A, Pan IH, Fucharoen G, et al. Three major lineages of Asian Y chromosomes: Implications for the peopling of east and Southeast Asia. Hum Genet. 2002;110:80–8.